| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Hospital & Healthcare Services
|
Compare with Industry peers |
| Website | http://www.tejnaksh.com | |
| Market Cap | 50.78 Cr. | |
| Enterprise Value(EV) | 52.44 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.62 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 40.56 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 67.18 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 11.35 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 2.20 | Calculated using Price: 25.00 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 2.03 Cr. | 20,313,600 Shares |
| FaceValue | 5 | |
| About Tejnaksh Healthcare Ltd. | ||
| The company is an integrated healthcare delivery service provider, committed to delivering quality healthcare services to its patients in modern facilities. Its operations are divided across four key vertical streams in healthcare delivery, namely - “Pediatric Urologyâ€, “Adult Urology (Male, Female)â€, “Andrology and Sexual Dysfunction†and “Nephrology, Dialysis and Renal Transplantâ€. It offers a gamut of more than 65 healthcare services under these streams. A base of over 65 employees and consultants supports its healthcare facility network. The company's healthcare facilities use advanced technology and its doctors, nurses and other healthcare professionals follow treatment protocols that match international standards. A majority of its healthcare facilities provide secondary, tertiary and quaternary healthcare services to patients. Some of its healthcare facilities provide super speciality quaternary healthcare to patients in key specialty areas such as Pediatric Urology and Adult Urology (Male, Female). | ||
| 1 Day |
|
|
| 1 Week |
|
+0.36% |
| 1 Month |
|
+2.20% |
| 3 Month |
|
-15.34% |
| 6 Month |
|
-15.74% |
| 1 Year |
|
-30.49% |
| 2 Year |
|
-68.88% |
| 5 Year |
|
+1.83% |
| 10 Year |
|
| 8 years | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 21.17 | 26.68 | 34.98 | 26.93 | 15.1 | 12.71 | 15.05 | 8.57 | |
| Return on Capital Employed (%) | 34 | 29.35 | 32.66 | 27.59 | 17.78 | 14.2 | 17.22 | 11.36 | |
| Return on Assets (%) | 19.32 | 16.96 | 17.97 | 14.93 | 9.1 | 8.36 | 10.38 | 5.89 |
| Particulars | 9 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 6 | 8 | 10 | 13 | 15 | 17 | 20 | 22 | 23 | |
| Non Curr. Liab. | 0 | 7 | 6 | 6 | 7 | 5 | 7 | 7 | 7 | |
| Curr. Liab. | 0 | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
| Minority Int. | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||
| Equity & Liab. | 7 | 16 | 20 | 22 | 25 | 25 | 30 | 31 | 32 | |
| Non Curr. Assets | 6 | 14 | 17 | 18 | 18 | 21 | 25 | 25 | 25 | |
| Curr. Assets | 1 | 2 | 3 | 5 | 7 | 3 | 5 | 6 | 6 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 7 | 16 | 20 | 22 | 25 | 25 | 30 | 31 | 32 |
| Particulars | 9 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 5 | 7 | 14 | 20 | 17 | 12 | 13 | 12 | 12 | |
| Other Income | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 5 | 7 | 15 | 21 | 17 | 12 | 13 | 12 | 12 | |
| Total Expenditure | -2 | -4 | -9 | -16 | -13 | -8 | -8 | -8 | -9 | |
| PBIDT | 2 | 3 | 6 | 6 | 4 | 4 | 5 | 4 | 3 | |
| Interest | 0 | -1 | -1 | -1 | -1 | 0 | -1 | -1 | ||
| Depreciation | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Exceptional Items | ||||||||||
| PAT | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 2 | 1 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Share Associate | 0 | |||||||||
| Other Related Items | ||||||||||
| Consolidated Net Profit | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 2 | 1 | |
| Adjusted EPS | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 4 | 2 | 4 | 3 | 1 | 1 | 9 | 2 | |
| Cash Fr. Inv. | -3 | -8 | -3 | -2 | -1 | 2 | -11 | -1 | |
| Cash Fr. Finan. | 0 | 6 | -1 | -2 | 0 | -3 | 2 | -1 | |
| Net Change | 0 | 1 | 1 | -1 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
|
Fri, 19 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Afrin Shaikh Designation: Company Secretary EmailId: cs.tejnaksh@gmail.com Name of the Chief Financial Officer: Ramesh Kuwar Designation: CFO EmailId: rdk.1963@rediffmail.com Date: 19/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Fri, 19 Apr 2024
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.
Date: 19/04/2024 |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Wed, 17 Apr 2024
Yearly Compliance Certificate (Financial Year Ended On March 31St 2024 Please Find Letter Attached |
||||||||||||||||||||||||||||||||||||||||||||||||||
| Wed, 24 Apr 2024 |
High Delivery Percentage
|
Close Within 52 Week Low Zone
|
High Decrease in 3 Months
|
High Decrease in 1 Year
|
High Decrease in 2 Years
|
